GJA3 | Gap junction protein, alpha 3, 46kDa | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
GLP1R | Glucagon-like peptide 1 receptor | FDA approved drug targets G-protein coupled receptors Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
GPR22 | G protein-coupled receptor 22 | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
GRIN2C | Glutamate receptor, ionotropic, N-methyl D-aspartate 2C | FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
GSG1L | GSG1-like | Predicted membrane proteins
| | | | | Tissue enhanced |
HAND1 | Heart and neural crest derivatives expressed 1 | Transcription factors
| | | | | Tissue enhanced |
HCN4 | Hyperpolarization activated cyclic nucleotide-gated potassium channel 4 | Disease related genes Potential drug targets Predicted membrane proteins Transporters Voltage-gated ion channels
| | | | | Tissue enhanced |
HSPB2 | Homo sapiens heat shock 27kDa protein 2 (HSPB2), mRNA. | | | | | | Tissue enhanced |
HSPB2-C11orf52 | HSPB2-C11orf52 readthrough (NMD candidate) | | | | | | Tissue enhanced |
HSPB7 | Heat shock 27kDa protein family, member 7 (cardiovascular) | | | | | | Tissue enhanced |
HSPB8 | Heat shock 22kDa protein 8 | Disease related genes
| | | | | Tissue enhanced |
IGSF5 | Immunoglobulin superfamily, member 5 | Predicted membrane proteins
| | | | | Tissue enhanced |
IRX6 | Iroquois homeobox 6 | Transcription factors
| | | | | Tissue enhanced |
LRRC49 | Leucine rich repeat containing 49 | | | | | | Tissue enhanced |
MASP1 | Mannan-binding lectin serine peptidase 1 (C4/C2 activating component of Ra-reactive factor) | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
METTL11B | Methyltransferase like 11B | Enzymes
| | | | | Tissue enhanced |
NDRG4 | NDRG family member 4 | Predicted membrane proteins
| | | | | Tissue enhanced |
NEBL | Nebulette | | | | | | Tissue enhanced |
NES | Nestin | Plasma proteins
| | | | | Tissue enhanced |
NEXN | Nexilin (F actin binding protein) | Cytoskeleton related proteins Disease related genes
| | | | | Tissue enhanced |
OXCT1 | 3-oxoacid CoA transferase 1 | Disease related genes Enzymes Mitochondrial proteins Potential drug targets Predicted secreted proteins
| | | | | Tissue enhanced |
P2RX3 | Purinergic receptor P2X, ligand-gated ion channel, 3 | Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
PALM2 | Paralemmin 2 | | | | | | Tissue enhanced |
PALM2-AKAP2 | PALM2-AKAP2 readthrough | | | | | | Tissue enhanced |
PAQR9 | Progestin and adipoQ receptor family member IX | Predicted membrane proteins
| | | | | Tissue enhanced |
PDE1C | Phosphodiesterase 1C, calmodulin-dependent 70kDa | Enzymes
| | | | | Tissue enhanced |
PDE3A | Phosphodiesterase 3A, cGMP-inhibited | Enzymes FDA approved drug targets Plasma proteins Predicted membrane proteins
| | | | | Tissue enhanced |
PEBP4 | Phosphatidylethanolamine-binding protein 4 | Plasma proteins Predicted secreted proteins
| | | | | Tissue enhanced |
PKIA | Protein kinase (cAMP-dependent, catalytic) inhibitor alpha | | | | | | Tissue enhanced |
PKP2 | Plakophilin 2 | Disease related genes Plasma proteins
| | | | | Tissue enhanced |
PLA2G5 | Phospholipase A2, group V | Disease related genes Enzymes Potential drug targets Predicted secreted proteins RAS pathway related proteins
| | | | | Tissue enhanced |
PLCXD3 | Phosphatidylinositol-specific phospholipase C, X domain containing 3 | | | | | | Tissue enhanced |
PLN | Phospholamban | Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
PPFIA4 | Protein tyrosine phosphatase, receptor type, f polypeptide (PTPRF), interacting protein (liprin), alpha 4 | Plasma proteins
| | | | | Tissue enhanced |
PPP1R14C | Protein phosphatase 1, regulatory (inhibitor) subunit 14C | | | | | | Tissue enhanced |
PPP1R3C | Protein phosphatase 1, regulatory subunit 3C | | | | | | Tissue enhanced |
PRKAA2 | Protein kinase, AMP-activated, alpha 2 catalytic subunit | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
PTGES3L | Prostaglandin E synthase 3 (cytosolic)-like | | | | | | Tissue enhanced |
PTPLA | Protein tyrosine phosphatase-like (proline instead of catalytic arginine), member A | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
QRFPR | Pyroglutamylated RFamide peptide receptor | G-protein coupled receptors Predicted membrane proteins
| | | | | Tissue enhanced |
RAB9B | RAB9B, member RAS oncogene family | Predicted secreted proteins
| | | | | Tissue enhanced |
RBM20 | RNA binding motif protein 20 | Disease related genes
| | | | | Tissue enhanced |
RBM24 | RNA binding motif protein 24 | | | | | | Tissue enhanced |
RBPMS2 | RNA binding protein with multiple splicing 2 | | | | | | Tissue enhanced |
RCAN2 | Regulator of calcineurin 2 | | | | | | Tissue enhanced |
RGS6 | Regulator of G-protein signaling 6 | | | | | | Tissue enhanced |
RP11-10A14.4 | Uncharacterized protein | Predicted membrane proteins
| | | | | Tissue enhanced |
RP11-650K20.3 | Uncharacterized protein | | | | | | Tissue enhanced |
RP11-849F2.7 | KRAB-A domain-containing protein 2 | | | | | | Tissue enhanced |
RRAD | Ras-related associated with diabetes | | | | | | Tissue enhanced |